Citation Impact
Citing Papers
Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER+ Breast Cancer
2016
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
2016
A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
2015
Chimeric antigen receptor -T cell therapy: Applications and challenges in treatment of allergy and asthma
2019
Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer
2016
Cancer immunotherapy beyond immune checkpoint inhibitors
2018
Old dogs, new trick: classic cancer therapies activate cGAS
2020
Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging
2006 Standout
The PI3K/AKT Pathway as a Target for Cancer Treatment
2015
Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality
2009 StandoutNobel
Aptamer mediated siRNA delivery
2006
Neoadjuvant Therapy in the Treatment of Breast Cancer
2014
The re-emergence of natural products for drug discovery in the genomics era
2015 Standout
Novel radiolabeled antibody conjugates
2007
Myeloid-derived suppressor cells coming of age
2018 Standout
A view on drug resistance in cancer
2019 StandoutNature
Breast cancer
2016 Standout
Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody
2005
Inflammation and Cancer: Triggers, Mechanisms, and Consequences
2019 Standout
Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells
2022 StandoutNobel
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Metabolic Reprogramming by the PI3K-Akt-mTOR Pathway in Cancer
2016
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Antibody-targeted radiation cancer therapy
2004
Clinical lessons learned from the first leg of the CAR T cell journey
2019
The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics
2013
Radiolabeled immunotherapy in non-Hodgkin's lymphoma treatment: the next step
2009
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
2021 Standout
Cancer Statistics, 2006
2006 Standout
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
2016
Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton
2016
CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity
2019 StandoutNobel
WHO-EORTC classification for cutaneous lymphomas
2005 Standout
Genetically engineered T cells for cancer immunotherapy
2019
Cancer stem cells revisited
2017 Standout
Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)
2015
Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients
2020
Antibody therapy of cancer
2012 Standout
Aptamers as therapeutics
2010 Standout
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Polymer conjugates as anticancer nanomedicines
2006 Standout
Radioimmunotherapy of non-Hodgkin’s lymphoma: a critical appraisal
2005
Aptamers as targeted therapeutics: current potential and challenges
2016 Standout
Radioimmunotherapy for Non-Hodgkin's Lymphoma
2005
Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view
2007
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
2016
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Matching chelators to radiometals for radiopharmaceuticals
2013 Standout
Primary Cutaneous T-Cell Lymphomas
2006
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable
2019 Standout
Targeting ferroptosis as a vulnerability in cancer
2022 Standout
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
AKT/PKB Signaling: Navigating the Network
2017 Standout
Clinical targeting of the TNF and TNFR superfamilies
2013
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
2018
The PI3K Pathway in Human Disease
2017 Standout
New developments for antibody-drug conjugate-based therapeutic approaches
2016
De novo design of tyrosine and serine kinase-driven protein switches
2021 StandoutNobel
Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy
2015
Glycosylation in cancer: mechanisms and clinical implications
2015 Standout
Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer
2015
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
2015
Arming antibodies: prospects and challenges for immunoconjugates
2005
Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent From Interferons
2017 StandoutNobel
The phosphoinositide 3-kinase pathway and therapy resistance in cancer
2015
Computational design of a synthetic PD-1 agonist
2021 StandoutNobel
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Practical Approach to Triple-Negative Breast Cancer
2017
Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity
2022 StandoutNobel
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
2005 Standout
In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism
2023 StandoutNobel
A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer
2013
Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges
2016
Toward a Global Understanding of Chemical Pollution: A First Comprehensive Analysis of National and Regional Chemical Inventories
2020 Standout
New Strategies for Fluorescent Probe Design in Medical Diagnostic Imaging
2009 Standout
Pivotal Study of Iodine-131–Labeled Chimeric Tumor Necrosis Treatment Radioimmunotherapy in Patients With Advanced Lung Cancer
2005
A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast Cancer
2016
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Information Retrieval and Text Mining Technologies for Chemistry
2017
Cancer treatment and survivorship statistics, 2016
2016 Standout
Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program
2014
Antibody-Targeted Chemotherapy with the Calicheamicin Conjugate hu3S193- N -Acetyl γ Calicheamicin Dimethyl Hydrazide Targets Lewisy and Eliminates Lewisy-Positive Human Carcinoma Cells and Xenografts
2004
Metabolic reprogramming and cancer progression
2020 StandoutScience
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
2015 Standout
Analysis of nanoparticle delivery to tumours
2016 Standout
The Tumor Microenvironment Innately Modulates Cancer Progression
2019 Standout
Asah2 Represses the p53–Hmox1 Axis to Protect Myeloid-Derived Suppressor Cells from Ferroptosis
2021
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
Simple Sugars to Complex Disease—Mucin-Type O-Glycans in Cancer
2015
Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer
2018
Clinical Translation of Nanomedicine
2015
Works of Andres Forero being referenced
Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma
2016
Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody
2016
Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration
2017
High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort
2017
Phase I Study of 90 Y-CC49 Monoclonal Antibody Therapy in Patients with Advanced Non-Small Cell Lung Cancer: Effect of Chelating Agents and Paclitaxel Co-Administration
2005
A Novel Monoclonal Antibody Design for Radioimmunotherapy
2003
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer
2015
Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer
2013
Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
2014
Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006
2013
Randomized Phase II Trial of Weekly vs. Every 2 Weeks vs. Every 3 Weeks Nanoparticle Albumin-Bound Paclitaxel With Bevacizumab as First-Line Chemotherapy for Metastatic Breast Cancer
2013
Physical Activity and Sleep Quality in Breast Cancer Survivors
2017
GenDrux: A biomedical literature search system to identify gene expression-based drug sensitivity in breast cancer
2011
History of antibody therapy for non-Hodgkin’s lymphoma
2003
Initial phase II results of SGN-30 (anti-CD30 monoclonal antibody) in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL)
2005
Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2mut MBC).
2016
Abstract P3-14-05: Interim analysis of a phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with metastatic breast cancer
2016
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma
2004
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies
2007
METRIC: A randomized international study of the antibody-drug conjugate glembatumumab vedotin (GV or CDX-011) in patients (pts) with metastatic gpNMB-overexpressing triple-negative breast cancer (TNBC).
2015
Extended phase I trial of the oral pan-Bcl-2 inhibitor AT-101 by multiple dosing schedules in patients with advanced cancers
2009
Abstract P6-10-05: SU2C Phase 1b Trial of Dual PI3K/ mTOR Inhibitor BEZ235 with Letrozole in ER+/HER2− Metastatic Breast Cancer (MBC)
2012
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
2019
Abstract PD1-2: PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab and without chemotherapy in TBCRC006, a neoadjuvant trial of HER2-positive breast cancer patients
2013
Abstract P6-10-01: A randomized phase 2 study of the antibody-drug conjugate CDX-011 in advanced GPNMB-overexpressing breast cancer: The EMERGE study
2012
Case report of a patient with primary central nervous system lymphoma treated with radioimmunotherapy.
2006
First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors
2017